News | April 15, 2009

Evaluation of Medtronic’s Endurant Stent Graft Begins

April 15, 2009 - Medtronic Inc. today announced the initiation of the global abdominal aortic aneurysm study known as ENGAGE, which will evaluate the performance of the Endurant stent graft, designed to provide an advanced minimally invasive alternative to open surgical repair of abdominal aortic aneurysms.
“ENGAGE seeks to involve more patients, at more sites and in more countries than any previous study of its kind,” said Robert Fitridge, M.D., The Queen Elizabeth Hospital in Adelaide, Australia, one of the study’s seven executive committee members. “The data this multicenter international study collects on the Endurant stent graft will help physicians worldwide determine how best to treat abdominal aortic aneurysms in the real-world setting of standard clinical practice.”
ENGAGE is expected to enroll 1,200 patients with abdominal aortic aneurysms at up to 80 medical centers across six continents. Patients who meet the single-arm study’s inclusion criteria will be treated with the Endurant system and followed for five years. The study’s primary endpoint is treatment success at 12 months. Treatment success is a composite endpoint that requires the satisfaction of several criteria. These criteria include successful technical delivery and deployment of the stent graft as well as freedom from: aneurysm swelling; endoleaks; aneurysm rupture; conversion to surgery; graft migration; and graft occlusion.
Dr. Fitridge led the team that enrolled the first patient in this global post-market study on March 24. The other six ENGAGE executive committee members include: Drs. Dittmar Böckler of the University of Heidelberg in Germany; Paul Hayes of Addenbrookes Hospital in Cambridge, England; Furuzan Numan of Memorial Hospital in Istanbul, Turkey; Juan Carlos Parodi of FLENI in Buenos Aires, Argentina; Vicente Riambau of Hospital Clínico de Barcelona in Spain; and Yehuda Wolf of Sourasky Medical Center in Tel-Aviv, Israel.
Use of the Endurant stent graft system in the U.S. is limited to an investigational clinical trial.
For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init